BEFORE

What the Client Provided

Veru shared its working corporate deck, version 17 with 65 slides, along with earlier versions and its public conference deck. As new trial results and an oncology program were added, the presentation had grown slide by slide. Long bullet lists, dense tables, and figures copied from publications made it difficult to identify the main point quickly.

The challenge was to help investors follow the story, understand the evidence, and distinguish between the two programs without losing important detail.

Pain-Points

Text-heavy slides
No clear takeaways
Templated, inconsistent design
Science pasted from publications

Key messages were buried in paragraphs and nested bullets, so investors had to read instead of scan.

Before version of an oncology rationale slide with dense, text-heavy contentBefore version of the daraxonrasib slide written as dense bullet pointsBefore version of the intellectual property slide written as long text

Titles described topics instead of conclusions, and the most important data had no visual emphasis.

Before version of a regulatory slide built from long paragraphs of text with no visual hierarchyBefore version of the primary endpoint slide with a dense data table and no highlighted resultBefore version of the safety slide with a plain table and no highlighted result

Stock template elements, clashing colors, and generic shapes made every slide carry the same weight.

Before version of the obesity program milestones slide built on a generic templateBefore version of the oncology milestones slide built on a generic templateBefore version of the appendix divider using the stock template

Pathway and mechanism figures were screenshots from journals, each in a different style and resolution.

Before version of a preclinical oncology slide crowded with pasted publication figuresBefore version of a resistance mechanism slide with a pasted pie chart and pathway figureBefore version of a sabizabulin slide crowded with pasted xenograft charts
THE PROCESS

From a 65-Slide Working Deck to One Investor Story

01

Discover

Kick-off calls with Veru's investor relations lead and CEO on audience, goals, and every slide.

02

Structure

A wireframe-only pass: story order, section breakers, and eyebrow navigation.

03

Direction

Two design explorations benchmarked against leading biotech decks. Option 1 approved.

04

Design

73 slides with custom illustrations and rebuilt charts, every number checked against source.

05

Support

Conference and roadshow updates, plus a standalone obesity-program deck.

STEP 1

Restructuring the Story Before Designing It

Each program needed its own logical progression while remaining part of the same corporate presentation. We organized the content around the questions an investor would need answered: Who is affected? What is Veru developing? What does the evidence show? What comes next?

Section dividers, small section labels, and program-specific colors helped make that progression visible throughout the deck.

Improvements

Logical Flow

Section Breakers

Eyebrow Navigation

Color-Coded Programs

CompanyCoverPipelineCardiometabolic Obesity ProgramWho is at riskEnobosarmPhase 2b QUALITY dataRegulatory pathWeight-loss plateauPhase 2b PLATEAUSupporting evidenceCompetition & marketMilestonesOncology ProgramPancreatic cancerKRAS to TUBB3 problemSabizabulinPreclinical & clinical proofPath forwardMilestonesAppendixIP & regulatory exclusivityScience in depth
Cover slide of the Veru Inc. corporate presentation, focused on cardiometabolic disease and oncology, with older adults walking on a beachDrug candidate pipeline slide from the Veru biopharma investor presentation, with color-coded obesity and oncology programs
Cardiometabolic Obesity Program section divider in hunter green from the Veru corporate presentationProblem slide showing why older sarcopenic patients with obesity are at the highest risk on GLP-1 drugs, with custom risk illustrationsPrimary endpoint slide highlighting full preservation of lean mass with enobosarm 3 mg in the Phase 2b QUALITY trialStair climb physical function slide with a custom illustration comparing placebo and enobosarm patientsWeight loss plateau slide pairing SELECT and SURMOUNT-1 trial charts in one clean comparisonObesity program clinical milestones timeline slide from 2026 to 2027
Oncology Program section breaker in Veru purple from the corporate presentationPancreatic cancer overview slide with large statistics on new cases, deaths, and survivalKRAS-driven cancer slide with a custom cell signaling illustration redrawn in the Veru palettePreclinical pancreatic cancer slide with a custom pancreas illustration and journal publicationPhase 1b/2 clinical study summary slide organized into safety, efficacy, advantage, and opportunity blocksOncology program clinical milestones timeline slide for sabizabulin
Appendix section divider for intellectual property and regulatory exclusivity strategyEnobosarm intellectual property portfolio slide organized into clean content blocksSabizabulin intellectual property and regulatory protection slide for oncologyCustom human body illustration showing beta III tubulin expression across cancer types
STEP 2

Two Programs. One Visual System.

Veru's leadership wanted fewer words and more blocks. We moved supporting detail into footnotes, turned lines of data into blocks and charts, and kept type bold so it reads on conference-room screens. Hunter green carries the cardiometabolic program and Veru purple carries oncology.

Hunter Green + Leaf Green#2F6739 · #489D56Cardiometabolic program, highlights & pillsVeru Purple + Deep Purple#4F3579 · #3B285DOncology program, covers & dividersLavender#EDE8F5Transitions & soft backgrounds
Obesity market opportunity slide sizing the global obesity and US sarcopenic obesity marketsPhase 2b QUALITY clinical trial design slide redesigned as a clear study flow for biotech investorsSupporting evidence slide with three charts showing lean mass, fat mass, and body weight changes
Preclinical pancreatic cancer slide with a custom pancreas illustration and journal publicationEnobosarm clinical product profile slide with efficacy and safety blocks and a custom molecule illustrationPreclinical bone data slide showing the dual anabolic and anti-resorptive effect of enobosarm
Unmet need transition slide stating the need for a therapy that achieves weight reduction while preserving muscle and functionSupporting Evidence section divider from the Veru corporate presentationKey problems with GLP-1 weight loss slide using custom patient illustrations for older adults
STEP 3

Transforming Key Slides

We rebuilt the slides that do the most work in investor conversations. Titles now state the conclusion, tables highlight the result that matters, charts are redrawn in brand colors, and text-heavy slides became structured blocks.

Improvements

Clear Takeaways

Blocks over Bullets

Data Visualization

Investor Ready

01CoverA stock template became a full-bleed brand cover that sets the tone in the first second.02PipelineA dense table became a clean, color-coded pipeline for both programs.03Primary endpointThe winning dose now sits in a highlighted column with three plain-language takeaways.04Weight-loss plateauTwo trial charts merged into one comparison, with the conclusion stated in the title.05Pancreatic cancerA bullet list became four headline statistics and a clear disease-burden summary.06Clinical summaryDense bullets were reorganized into safety, efficacy, advantage, and opportunity blocks.
Cover slide of the Veru Inc. corporate presentation, focused on cardiometabolic disease and oncology, with older adults walking on a beach
Before version of the Veru corporate presentation cover slide using a stock template
Drug candidate pipeline slide from the Veru biopharma investor presentation, with color-coded obesity and oncology programs
Before version of the Veru pipeline slide with a dense table and generic arrow shapes
Primary endpoint slide highlighting full preservation of lean mass with enobosarm 3 mg in the Phase 2b QUALITY trial
Before version of the primary endpoint slide with a dense data table and no highlighted result
Weight loss plateau slide pairing SELECT and SURMOUNT-1 trial charts in one clean comparison
Before version of the weight loss plateau slide with a chart copied from a publication
Pancreatic cancer overview slide with large statistics on new cases, deaths, and survival
Before version of the pancreatic cancer slide written as a long bullet list
Phase 1b/2 clinical study summary slide organized into safety, efficacy, advantage, and opportunity blocks
Before version of the Phase 1b/2 summary slide written as dense bullet points
BeforeAfter
Circular grid pattern composed of thin white intersecting lines on a black background.
CUSTOM ILLUSTRATIONS

From Journal Figures to Purpose-Built Illustrations

Veru's science lived in clip-art icons and figures copied from journals. We drew a custom illustration library in the Veru palette: patients aged 65 and over, a stair climb scene that makes the trial's functional endpoint visible, body composition figures, and redrawn mechanism-of-action diagrams. Hover the library to pause it, and click any piece to enlarge it.

Custom illustration of placebo and enobosarm patients climbing stairs to show the stair climb power result
Stair climb endpoint
Custom illustration of an older adult using a walker, representing sarcopenic obesity risk
Older adult at risk
Custom illustration of an arm showing muscle loss during GLP-1 weight loss
Muscle loss
Custom side-profile illustration of a patient with persistent obesity
Persistent obesity
Custom illustration of an older adult in a wheelchair representing mobility disability
Mobility disability
Custom illustration of a GLP-1 injection pen and vial
GLP-1 therapy
Custom before and after body composition illustration showing fat loss with preserved muscle
Body composition
Custom mechanism of action illustration showing how sabizabulin destabilizes microtubules and drives apoptosis
Mechanism of action
Custom cell illustration of the KRAS signaling network leading to beta III tubulin
KRAS signaling network
Custom pancreas anatomy illustration for the pancreatic cancer program
Pancreatic anatomy
Illustration of sabizabulin bound to the colchicine binding site on a microtubule
Sabizabulin binding site
Custom ball-and-stick illustration of the enobosarm molecule
Enobosarm molecule
Custom human body illustration mapping beta III tubulin expression across cancer types
βIII-tubulin across cancers
01

Patient population

Clip-art icons redrawn as patients aged 65 and over, Veru's target population.

Before version of the key problems slide using generic clip-art iconsKey problems with GLP-1 weight loss slide using custom patient illustrations for older adults
Before
After
02

Functional endpoint

A bar chart became a stair climb scene that makes the trial's key functional result visible.

Before version of the stair climb slide using a basic bar chartStair climb physical function slide with a custom illustration comparing placebo and enobosarm patients
Before
After
03

Mechanism of action

Pathway figures from journals rebuilt as one cell-signaling illustration in Veru's palette.

Before version of the KRAS-driven cancer slide using pathway figures pasted from publicationsKRAS-driven cancer slide with a custom cell signaling illustration redrawn in the Veru palette
Before
After
04

Disease landscape

A pasted journal figure redrawn as a clean body map of βIII-tubulin across cancers.

Before version of the beta III tubulin cancer slide using a figure copied from a journalCustom human body illustration showing beta III tubulin expression across cancer types
Before
After
Circular grid pattern composed of thin white intersecting lines on a black background.
AFTER

Key Slides from the Final Deck

The final corporate presentation positions Veru as a focused late clinical-stage company with two clear opportunities, from the patients at risk and the clinical evidence to the market and the oncology science.

Cover slide of the Veru Inc. corporate presentation, focused on cardiometabolic disease and oncology, with older adults walking on a beach
Cover
Stair climb physical function slide with a custom illustration comparing placebo and enobosarm patients
Stair climb result
Drug candidate pipeline slide from the Veru biopharma investor presentation, with color-coded obesity and oncology programs
Drug candidate pipeline
Problem slide showing why older sarcopenic patients with obesity are at the highest risk on GLP-1 drugs, with custom risk illustrations
Who is most at risk
Enobosarm clinical product profile slide with efficacy and safety blocks and a custom molecule illustration
Enobosarm profile
Key problems with GLP-1 weight loss slide using custom patient illustrations for older adults
Key problems, illustrated
Incremental weight loss slide with highlighted data column and custom body composition illustration
Incremental weight loss
Obesity market opportunity slide sizing the global obesity and US sarcopenic obesity markets
Market opportunity
Pancreatic cancer overview slide with large statistics on new cases, deaths, and survival
Pancreatic cancer overview
KRAS-driven cancer slide with a custom cell signaling illustration redrawn in the Veru palette
KRAS-driven cancer
Preclinical pancreatic cancer slide with a custom pancreas illustration and journal publication
Preclinical proof
Obesity program clinical milestones timeline slide from 2026 to 2027
Obesity milestones
01 / 12
SEE THE COMPLETE STORY

View the full deck on Veru's investor website

Veru publishes its latest corporate presentation on its investor relations site. Open it to flip through the full deck, slide by slide.

View full deckir.verupharma.com
CLIENT TESTIMONIAL

In Veru's Words

The overall process was smooth, communication was consistent, and the quality of their work was excellent.

Sam FischExecutive Director, Investor Relations and Corporate Communications, Veru Inc.
Highly responsiveStrong strategic guidanceOrganized and straightforwardConsistent communicationExcellent qualityDependable team
Samuel FischGoogle review5.0
★★★★★
I had a great experience working with Kirk and Harry at M’idea. From the beginning, they were highly responsive, thoughtful, and easy to work with. They provided strong strategic guidance throughout the process and took the time to clearly explain their recommendations, which made each step feel organized and straightforward. The overall process was smooth, communication was consistent, and the quality of their work was excellent. Kirk and Harry were professional, reliable, and genuinely invested in delivering a strong result. I would highly recommend M’idea to anyone looking for a knowledgeable and dependable team.
CONCLUSION

One Corporate Story.
Ready for Every Room.

Veru started with credible science and strong clinical data spread across a growing, text-heavy deck. The final corporate presentation brings both programs into one connected investor story, and the same visual language carries from the conference stage to the inbox.

73 Slides

A complete corporate presentation,built for roadshows, conferences, and email.

2 Programs

Cardiometabolic and oncology,each color-coded with its own clear flow.

Custom Illustration

Patients, function, and mechanism of action,drawn in Veru's palette.

Ongoing Partner

Conference and roadshow updatesdelivered long after the first full draft.